Subscribe to our Newsletters !!
Like never seen before, coral reefs across the
High capacity and performance combined with an int
Dr. Mohammed Enayat’s recent testimony on his ag
It is with utmost pride that Microbioz India annou
The world of pharmaceuticals encompasses a broad s
For some time now,
In our cover story, we shine a spotlight on “ The Magazine
Drug firm FDC Ltd on Tuesday said it has established two variants of this COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had previously approved the use of Favipiravir, an off patent, oral antiviral drug that’s been demonstrated to quicken clinical healing from COVID-19 patients with mild to moderate symptoms, FDC said in a statement.
“Early diagnosis and treatment will aid in arresting the deteriorating condition of patients, and we’ll be working with the authorities and health care fraternity to create Favenza and PiFLU available across the nation” FDC spokesperson Mayank Tikkha said.
Both the products are currently available across the nation, the company said.
The price per tablet computer is Rs 55 for both the versions, it included.
